Department of Cardiology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200127, China. huangmeirong128@sina.com
Abstract OBJECTIVE: Anthracyclines (ANT) are effective for leukemia and solid tumors. However the long-term life quality of patients is seriously affected by ANT-related cardiotoxicity. The aim of this study was to evaluate the value of two dimension echocardiography (2DE) and serum biochemical indicators in monitoring ANT-related cardiotoxicity. METHODS: Seventy children who received ANT chemotherapy (ANT dose: 124±73 mg/m2) and were followed up for 22±13 months were enrolled. 2DE with aspects of conventional indexes (left ventricular diameter and wall thickness, ejection fraction, E/A), myocardial performance index (MPI) and tissue Doppler imaging (TDI) were performed. Serum levels of troponin (CTnI) and brain natriuretic peptide (BNP) were measured. Thirty-seven healthy children served as the control group. RESULTS: There were no significant differences in conventional indexes of 2DE between the ANT and the control groups. The MPI of left and right ventricular in the ANT group increased significantly compared with that in the control group (0.237±0.06 vs 0.203±0.06, 0.171±0.05 vs 0.140±0.04 respectively; P<0.01). TDI showed the late diastolic peak velocity in the basal and middle sections of left ventricular, interventricular septum and right ventricular in the ANT group were significantly higher than the controls. There were significant differences in the ratio of early to late diastolic peak velocity of the middle section of left ventricular and the basal and middle sections of the interventricular septum between the two groups (P<0.05). The changes of MPI and TDI became more obvious with the increased dose of ANT. There were no significant differences in serum CtnI and BNP levels between the two groups. CONCLUSIONS: The heart function of patients who received ANT chemotherapy needs to be monitored for a long term. MPI and TDI can be used as early indexes for monitoring the heart function.
XU Xin-Yi,HUANG Mei-Rong,TANG Jing-Yan et al. Evaluation of early monitoring of cardiotoxicity induced by anthracyclines[J]. 中国当代儿科杂志, 2011, 13(6): 490-494.
XU Xin-Yi,HUANG Mei-Rong,TANG Jing-Yan et al. Evaluation of early monitoring of cardiotoxicity induced by anthracyclines[J]. CJCP, 2011, 13(6): 490-494.
［1］Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group［J］. J Clin Oncol, 2001, 19(7):1926-1934.
［2］Guimaraes-Filho F, Tan D, Braga J, Rodrigues A, Waib P, Matsubara B. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines［J］. Am J Cardiol, 2007, 100(8): 1303-1306.
［5］Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines［J］. Circulation, 2005, 112(12): e154-e235.
［6］Adams MJ, Lipshultz SE. Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention［J］. Pediatr Blood Cancer, 2005, 44(7): 600-606.
［7］Santin JC, Deheinzelin D, Junior SP, Lopes LF, de Camargo B. Late echocardiography assessment of systolic and diastolic function of the left ventricle in pediatric cancer survivors after anthracycline therapy［J］. J Pediatr Hematol Oncol, 2007, 29(11): 761-765.
［8］Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N,et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors［J］. J Clin Oncol, 2007, 25(24): 3635-3643.
［9］Rathe M, Carlsen NL, Oxhoj H, Nielsen G. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia［J］. Pediatr Blood Cancer, 2010, 54(3): 444-448.
［10］Ishii M, Tsutsumi T, Himeno W, Eto G, Furui J, Hashino K, et al. Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy［J］. Am J Cardiol, 2000, 86(11): 1279-1281.
［11］Eidem BW, Sapp BG, Suarez CR, Cetta F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children［J］. Am J Cardiol, 2001, 87(9): 1120-1122.
［12］Nagy AC, Cserép Z, Tolnay E, Nagykálnai T, Forster T. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study［J］. Pathol Oncol Res, 2008, 14(1):69-77.
［13］Stapleton GE, Stapleton SL, Martinez A, Ayres NA, Kovalchin JP, Bezold LI, et al.Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines［J］.J Am Soc Echocardiogr, 2007, 20(5): 492-497.
［14］Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity［J］.Pediatr Blood Cancer, 2008, 51(3): 327-333.
［15］Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review［J］.Eur J Cancer, 2007, 43(13): 1959-1966.
［16］Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults［J］. Clin Res Cardiol, 2008, 97(5): 318-326.
